Disease-specific solutions backed by clinical data.

The Zenith portfolio of endovascular products and services are designed to treat more patients with a durable repair.

**At 5 years:**

Clinical Update on Zenith Alpha® Thoracic

- 0% migration > 10 mm*
- 0 proximal type I, III, or IV endoleaks
- 99% freedom from TAA-related mortality
- 0 component separations
- 0 ruptures

**Source:** Zenith Alpha Thoracic 2017 clinical update. 110 patients were included in the global clinical study.

*Based upon new presentation at 5 years. (3 patients had cranial migration of the distal end, first noted at 2 years).